How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,323 results for

aspirin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Canadian Stroke Best Practice recommendations, seventh edition: acetylsalicylic acid for prevention of vascular events

sequential analysis of randomized controlled trials. Eur Heart J 2019;40:607-17. 7. O’Brien CW, Juraschek SP, Wee CC. Prevalence of aspirin use for primary pre- vention of cardiovascular disease in the United States: results from the 2017 National Health Interview Survey. Ann Intern Med 2019 July 23 [Epub ahead of print]. doi: 10.7326/M19-0953. 8. Acetylsalicylic acid (ASA). Whitby (ON): Thrombosis Canada; 2018. Available: https://thrombosiscanada.ca/wp-content/uploads/2019/01/Acetylsalicyclic-Acid (...) % more people die of heart conditions, stroke or vascular cognitive impairment than die from all cancers combined. 1 The benefits of acetylsalicylic acid (ASA) for secondary pre- vention of atherosclerotic cardiovascular disease are well estab- lished. In contrast, although low-dose ASA therapy for primary prevention of atherosclerotic cardiovascular disease was once commonly recommended, this practice is now being recon- sidered in light of recent evidence. Three large randomized con- trolled trials

2020 CPG Infobase

2. Acetyl Salicylic Acid (ASA)

Acetyl Salicylic Acid (ASA) © 2015 Thrombosis Canada Page 1 of 4 ACETYL SALICYLIC ACID (ASA) OBJECTIVE: To provide information on the use of acetyl salicylic acid in the prevention of vascular thromboembolic events. BACKGROUND: Acetyl salicylic acid (ASA) is well-established in the management of acute myocardial infarction and in the secondary prevention of cardiovascular disease among both men and women, based on large randomized trials. More recently, its role in the prevention of recurrent (...) venous thromboembolism has been demonstrated. The net benefit of ASA use depends on weighing the anticipated reduction in cardiovascular events against the increased risk of gastrointestinal bleeding. MECHANISM OF ACTION OF ASA: ASA irreversibly inhibits platelet aggregation by inhibiting thromboxane A 2 (TxA 2 ) synthesis. INDICATIONS FOR ASA: Antiplatelet therapy is recommended for all patients with the following, unless contraindicated: 1) Cardiac: For all patients with symptomatic coronary artery

2015 Thrombosis Interest Group of Canada

3. Acetylsalicylic acid (ASA) for primary prevention of cardiovascular disease

profile and consult your decision boxes. Email Password Stay logged in: Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. Create an account Title Full Name Email * Choose a username Password * Please enter a password Repeat Password * Both passwords do not fit Aspirin for cardiovascular disease Acetylsalicylic acid (ASA) for primary prevention of cardiovascular disease Presenting ASA to patients To know more (...) Acetylsalicylic acid (ASA) for primary prevention of cardiovascular disease Boîte à décision | Pdf boxe Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. I do not have an account Provide some personal information and create a user account allowing to save your Decision box results and view them later. You can also: I already have an account Please enter your email address and password to access your

2014 Cancer Council Australia

4. APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators

APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators APSF/ASA Guidance on Purposing Anesthesia Machines as ICU Ventilators Anesthesia machines are equipped with ventilators that in many cases are capable of providing life-sustaining mechanical ventilation to patients with respiratory failure. They are used for this purpose every day in the operating room. FDA approved labeling does not provide for using anesthesia ventilators for long term ventilatory support. Nevertheless (...) anesthesia machines safely and effectively as ICU ventilators. Detailed information is provided below and a quick reference guide is available for downloading. The quick reference guide is intended to be a bedside tool and includes a suggested schedule for monitoring the effectiveness and safety of the anesthesia ventilator. ASA is working with component societies to develop an inventory of local resources with the goal of moving machines to the locations where they are most needed. (NOTE: Local

2020 American Society of Anesthesiologists

5. ASA/ACS/AORN/AHA Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic

ASA/ACS/AORN/AHA Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back (...) Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News April 17, 2020 Joint Statement: Roadmap for Resuming Elective Surgery after COVID-19 Pandemic American College of Surgeons American Society of Anesthesiologists Association of periOperative Registered Nurses American Hospital Association (PDF) Introduction: In response to the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS

2020 American Society of Anesthesiologists

6. The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus

The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Podcasts Back Podcasts Quality and Practice Management Back Quality (...) and Practice Management Research and Publications Back Research and Publications Member Center Back Member Center About ASA Back About ASA News April 29, 2020 The ASA and APSF Joint Statement on Perioperative Testing for the COVID-19 Virus (PDF) Patients who are infected with SARS-CoV-2, the virus responsible for the COVID-19 disease, have higher perioperative morbidity and mortality. (1-3) Unexpected progression to acute respiratory distress syndrome, cardiac injury, kidney failure and even deaths has

2020 American Society of Anesthesiologists

7. Kaiser Permanente National Aspirin Clinician Guide

Kaiser Permanente National Aspirin Clinician Guide This Clinician Guide expires within two years of the posted month. 1 See National Clinical Library for current version (https://cl.kp.org). Aspirin Clinician Guide October 2018 Introduction These recommendations were developed to assist primary care physicians and other clinicians in aspirin use. The KP National Integrated Cardiovascular Health Guideline team adopted the 2016 aspirin recommendations developed by the United States Preventive (...) Services Task Force (USPSTF) on “Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication” for patients without Atherosclerotic Cardiovascular Disease (ASCVD). It is not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by practitioners. Aspirin Therapy at 81 mg Orally Daily for Adults without ASCVD Risk Assessment ? 10-year ASCVD Risk is risk of fatal or nonfatal myocardial infarctions or strokes in adults. A region may

2019 Kaiser Permanente National Guideline Program

8. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including (...) cardiovascular event prevention, and risks including serious bleeding events. Overall the studies suggest that aspirin lacks net benefit (total benefits minus total harms) beyond age 70, and there is low net benefit in younger adults. USPSTF 2016 aspirin recommendations point to highest net benefit for aspirin in adults age 50-59 (lower bleeding risk than older patients) with 10-year ASCVD risk* >10%. The National Kaiser Permanente Aspirin recommendations will be formally updated following a comprehensive

2019 Kaiser Permanente National Guideline Program

9. AHA/ASA Guidelines for Adult Stroke Rehabilitation and Recovery

AHA/ASA Guidelines for Adult Stroke Rehabilitation and Recovery Guidelines for Adult Stroke Rehabilitation and Recovery | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Guidelines for Adult Stroke Rehabilitation and Recovery A Guideline for Healthcare Professionals From the American Heart (...) of evidence and consensus. It is hoped that the relative proportion of recommendations based on rigorous evidence will grow over time. This guideline uses the framework established by the American Heart Association (AHA) concerning classes and levels of evidence for use in guidelines, as shown in 1 and 2. Table 1. Applying Classification of Recommendations and Level of Evidence Table 2. Definition of Classes and Levels of Evidence Used in AHA/ASA Recommendations Class I Conditions for which

2016 American Heart Association

10. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment

2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment 3020 Purpose—The aim of this guideline is to provide a focused update of the current recommendations for the endovascular treatment of acute ischemic stroke. When there is overlap, the recommendations made here supersede those of previous guidelines. Methods—This focused update analyzes results from 8 randomized, clinical trials of endovascular (...) the express permission of the American Heart Association. Instructions for obtaining permission are located at http://www.heart.org/HEARTORG/General/Copyright- Permission-Guidelines_UCM_300404_Article.jsp. A link to the “Copyright Permissions Request Form” appears on the right side of the page. © 2015 American Heart Association, Inc. Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STR.0000000000000074 AHA/ASA Guideline Downloaded from http://ahajournals.org by on March 27, 2019Powers et

2015 Congress of Neurological Surgeons

11. 2015 aha/asa focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment Full Text available with Trip Pro

2015 aha/asa focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 February 2019 January 2019

2015 American Academy of Neurology

12. Low-Dose Aspirin Use During Pregnancy

). Pathophysiology Aspirin (acetylsalicylic acid) is a nonsteroidal antiin- flammatory drug (NSAID) that works primarily through its inhibition of two cyclooxygenase isoen- zymes (COX-1 and COX-2), which are necessary for prostaglandin biosynthesis. The COX-1 isoform is present in the vascular endothelium and regulates the production of prostacyclin and thromboxane A 2 , pros- taglandins with opposing regulatory effects on vascular homeostasis and platelet function. Prostacyclin is a potent vasodilator (...) ) or hypersensitivity to other salicylates are at risk of anaphylaxis and should not receive low-dose aspirin. Because of significant cross-sensitivity between aspirin and other nonsteroidal drugs, low-dose aspirin is also contraindicated in patients with known hypersensi- tivity to NSAIDs. Exposure to low-dose aspirin in pa- tients with nasal polyps may result in life-threatening bronchoconstriction and should be avoided. The same is true in patients with asthma who have a history of aspirin-induced acute

2018 American College of Obstetricians and Gynecologists

13. Low-Dose Aspirin Use During Pregnancy

). Pathophysiology Aspirin (acetylsalicylic acid) is a nonsteroidal antiin- flammatory drug (NSAID) that works primarily through its inhibition of two cyclooxygenase isoen- zymes (COX-1 and COX-2), which are necessary for prostaglandin biosynthesis. The COX-1 isoform is present in the vascular endothelium and regulates the production of prostacyclin and thromboxane A 2 , pros- taglandins with opposing regulatory effects on vascular homeostasis and platelet function. Prostacyclin is a potent vasodilator (...) ) or hypersensitivity to other salicylates are at risk of anaphylaxis and should not receive low-dose aspirin. Because of significant cross-sensitivity between aspirin and other nonsteroidal drugs, low-dose aspirin is also contraindicated in patients with known hypersensi- tivity to NSAIDs. Exposure to low-dose aspirin in pa- tients with nasal polyps may result in life-threatening bronchoconstriction and should be avoided. The same is true in patients with asthma who have a history of aspirin-induced acute

2018 American College of Obstetricians and Gynecologists

14. ASA Physical Status Classification System

ASA Physical Status Classification System ​ASA Physical Status Classification System | American Society of Anesthesiologists (ASA) Menu Menu Close Standards and Guidelines Back Standards and Guidelines Advocacy & ASAPAC Back Advocacy & ASAPAC Education and Career Back Education and Career Events Back Events In the Spotlight Back In the Spotlight Quality and Practice Management Back Quality and Practice Management Research and Publications Back Research and Publications Member Center Back Member (...) Center About ASA Back About ASAASA Physical Status Classification System Developed By: ASA House of Delegates/Executive Committee Last Amended: October 15, 2014 (original approval: October 15, 2014) Current definitions (NO CHANGE) and Examples (NEW) ASA PS Classification Definition Examples, including, but not limited to: ASA I A normal healthy patient Healthy, non-smoking, no or minimal alcohol use ASA II A patient with mild systemic disease Mild diseases only without substantive functional

2014 American Society of Anesthesiologists

15. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication Recommendation | United States Preventive Services Taskforce Toggle navigation Main navigation Main navigation Recommendation to see the latest documents available. Recommendation Summary Population Recommendation Adults aged 50 to 59 years with a ≥10% 10-year CVD risk The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (...) (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years. B Adults aged 60 to 69 years with a ≥10% 10-year CVD risk The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who

2016 U.S. Preventive Services Task Force

16. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

aspirin use to reduce the risk for preeclampsia, preterm birth, and intrauterine growth restriction in women at high risk for preeclampsia. Other Relevant USPSTF Recommendations The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 µg) of folic acid. These recommendations are available at . For a summary of the evidence systematically reviewed in making these recommendations, the full recommendation statement, and supporting (...) -eclampsia and its complications. Cochrane Database Syst Rev . 2007;(2):CD004659. 11. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet . 2007;369:1791-8. 12. Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sørensen HT, Bonde JP, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. Epidemiology . 2010;21(6):779

2014 U.S. Preventive Services Task Force

17. Hyperacute stroke management. Acute ASA therapy. In: Canadian best practice recommendations for stroke care.

Hyperacute stroke management. Acute ASA therapy. In: Canadian best practice recommendations for stroke care. Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here Guidelines

2010 Canadian Stroke Network

18. Colorectal cancer

(including off-label use), professional guidelines, standards and laws (including on consent and mental capacity), and safeguarding. 1.1 1.1 Prevention Prevention of colorectal cancer in people with of colorectal cancer in people with Lynch syndrome Lynch syndrome 1.1.1 Consider daily aspirin [1] , to be taken for more than 2 years, to prevent colorectal cancer in people with Lynch syndrome. T o find out why the committee made the recommendation on prevention of colorectal cancer in people with Lynch (...) or no preoperative treatment, offer: capecitabine in combination with oxaliplatin (CAPOX) for 3 months, or if this is not suitable oxaliplatin in combination with 5-fluorouracil and folinic acid (FOLFOX) for 3 to 6 months, or single-agent fluoropyrimidine (for example, capecitabine) for 6 months, in line with NICE technology appraisal guidance (see adjuvant treatment of stage III colon cancer in the NICE Pathway on colorectal cancer). Base the choice on the person's histopathology (for example pT1-T3 and pN1

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

19. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing

of 47antiphospholipid syndrome or extreme body weight (less than 50 kg or more than 120 kg), consider carrying on with the current treatment if it is well tolerated. [2020] [2020] 1.4.10 If anticoagulation treatment fails follow the recommendation on treatment failure. [2020] [2020] 1.4.11 For people who decline continued anticoagulation treatment, consider aspirin 75 mg or 150 mg daily [6] . [2020] [2020] 1.4.12 Review general health, risk of VTE recurrence, bleeding risk and treatment preferences at least once (...) a year for people taking long-term anticoagulation treatment or aspirin. [2020] [2020] For a short explanation of why the committee made the 2020 recommendations on reviewing anticoagulation treatment and how they might affect practice, see rationale and impact. Full details of the evidence and the committee's discussion are in: • evidence review F: what factors determine the optimum duration of pharmacological treatment for DVT or PE in people with a VTE? • evidence review D: pharmacological

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

20. Twin and triplet pregnancy

pregnancy compared with women with a singleton pregnancy. [2011] [2011] 1.2.4 Perform a full blood count at 20 to 24 weeks to identify women with a twin or triplet pregnancy who need early supplementation with iron or folic acid (this is in addition to the test for anaemia at the routine booking appointment recommended in NICE's guideline on antenatal care for uncomplicated pregnancies). Repeat at 28 weeks as in routine antenatal care. [2011] [2011] 1.3 Delivery of antenatal and intrapartum care (...) on antenatal care for uncomplicated pregnancies. [2011] [2011] 1.6.2 Advise women with a twin or triplet pregnancy to take low-dose aspirin [1] daily from 12 weeks until the birth of the babies if they have 2 or more of the risk factors specified in NICE's guideline on hypertension in pregnancy. [2011, [2011, amended 2019] amended 2019] Twin and triplet pregnancy (NG137) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 20

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

Guidelines

Guidelines – filter by country